<DOC>
	<DOCNO>NCT01917019</DOCNO>
	<brief_summary>This multicenter study conduct 3 part . Part A double-blind placebo-controlled parallel-group period , Part B C open-label extension period . The primary objective double-blind study ( Part A ) ass effect Prolonged-Release Fampridine treatment walk speed measure T25FW ( time 25 foot walk ) Japanese participant Multiple Sclerosis . The secondary objective double-blind portion study evaluate safety tolerability prolonged-release Fampridine study population . The primary objective open-label extension study ( Part B ) evaluate long-term safety profile prolonged-release Fampridine . The primary objective additional open-label extension ( Part C ) provide participant complete study continue access prolonged-release fampridine market drug use applicable site sponsor decision discontinue study .</brief_summary>
	<brief_title>A Safety Efficacy Study Oral Prolonged-Release Fampridine ( BIIB041 ) Japanese Participants With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Part A To eligible participate Part A , candidate must meet following eligibility criterion screen timepoint specify individual eligibility criterion list ( potential subject fail screening may rescreened 1 time ) : 1 . Must diagnosis primaryprogressive , secondary progressive , progressive relapsing , relapsingremitting MS define revise McDonald Committee criterion ( [ Lublin Reingold 1996 ; McDonald 2001 ; Polman 2005 ] ) least 2 month duration . 2 . Must able complete T25FW without walk aid 8 45 second screen visit . Part B To eligible participate Part B , candidate must meet follow criterion Week 21 visit Part A , first visit Part B : 1 . Completed visit Part A study . Part C To eligible participate Part C , candidate must meet follow criterion Week 52 visit Part B , first visit Part C : 1 . Completed visit Part B study . Key 1 . Known allergy pyridinecontaining substance , inactive ingredient prolongedrelease fampridine tablet 2 . Any prior history seizure , epilepsy , convulsive disorder , exception febrile seizure childhood , prior history epileptiform activity electroencephalogram . 3 . Any form renal impairment define creatinine clearance ( CrCl ) &lt; 80 mL/min ( estimated central laboratory ) . 4 . Known history cardiac arrhythmia cardiac conduction disorder require medical surgical intervention , clinically significant ECG abnormality ( determined Investigator ) screen visit Day 1 . 5 . Any prior treatment fampridine ( 4 AP ) 3,4 diaminopyridine formulation . 6 . Treatment investigational drug approve therapy investigational use within 30 day ( 5 half life , whichever long ) prior screen visit . 7 . Participation investigational study ( exception observational study ) within 30 day prior screen visit plan enroll another interventional investigational study time study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Japan</keyword>
</DOC>